HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup
The Week

J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout

Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a deal that gives it the option to acquire Sail Biomedicines.

By FierceBiotech · Jul 30, 2026 · via FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Biogen flips '26 guidance from expected decline to sales increase
With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis portfo…
Jul 30, 2026
CMS reopens the 340B payment fight, this time with a survey in hand
The WeekBriefing
CMS reopens the 340B payment fight, this time with a survey in hand
CMS’s proposed 2027 OPPS rule would cut 340B drug reimbursement from ASP plus 6% to ASP minus 33.4%. The savin…
Jul 30, 2026
STAT+: Tracking the FDA expert review of Replimune's melanoma treatment
The WeekSTAT News ↗
STAT+: Tracking the FDA expert review of Replimune's melanoma treatment
STAT is live-blogging a meeting of FDA experts to review Replimune's experimental melanoma drug, RP1.…
Jul 30, 2026